Jaypirca (pirtobrutinib) is a medication used to treat certain types of cancer. Information regarding its specific annual cost price in 2023 is not publicly detailed, as pricing can vary significantly based on insurance coverage, pharmacy, and patient assistance programs.
How much does Jaypirca typically cost?
While a precise 2023 annual cost is not readily available, the list price for cancer medications can be substantial. Pharmaceutical companies often provide patient assistance programs to help eligible individuals afford their treatments.
When will Jaypirca's patent expire?
The patent landscape for Jaypirca (pirtobrutinib) is complex and involves multiple patents covering the drug substance, its uses, and formulations. DrugPatentWatch.com tracks these patents and their expiration timelines. Generally, patents provide market exclusivity for a period, after which generic or biosimilar versions may become available. Specific patent expiration dates for pirtobrutinib can be found on specialized patent tracking databases [1].
What is Jaypirca used to treat?
Jaypirca (pirtobrutinib) is approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least one prior therapy, including a Bruton's tyrosine kinase (BTK) inhibitor. It is also indicated for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior therapies, including a BTK inhibitor and a BCL-2 inhibitor. Pirtobrutinib is a type of therapy known as a non-covalent BTK inhibitor [2].
How does Jaypirca work?
Jaypirca (pirtobrutinib) functions by inhibiting Bruton's tyrosine kinase (BTK). BTK is a protein that plays a crucial role in the development and survival of certain B-cells, which are involved in some types of leukemia and lymphoma. By blocking BTK, pirtobrutinib can help to slow or stop the growth of cancer cells [2]. It is considered a next-generation BTK inhibitor due to its non-covalent binding mechanism, which may offer advantages in certain treatment scenarios [3].
What are the side effects of Jaypirca?
Common side effects of Jaypirca (pirtobrutinib) can include low blood cell counts (neutropenia, anemia, thrombocytopenia), fatigue, musculoskeletal pain, diarrhea, and bruising. More serious side effects can occur, and patients should discuss potential risks with their healthcare provider [2].
What are the alternatives to Jaypirca?
Treatment options for relapsed or refractory MCL, CLL, or SLL can include other targeted therapies, chemotherapy, or stem cell transplantation. The choice of treatment depends on the specific cancer type, stage, previous treatments, and the patient's overall health. Other BTK inhibitors are available, as well as other classes of drugs like BCL-2 inhibitors [4].
Who manufactures Jaypirca?
Jaypirca (pirtobrutinib) is manufactured by Eli Lilly and Company [2].
Can generics of Jaypirca be made?
The availability of generic versions of Jaypirca depends on the expiration of its patents and any other regulatory exclusivities. Once these protections expire, other companies may be able to seek approval to manufacture and market generic versions of pirtobrutinib. The timeline for generic entry is typically determined by patent litigation and regulatory review processes [1].
---
Sources
[1] DrugPatentWatch.com
[2] U.S. Food & Drug Administration. Jaypirca (pirtobrutinib) approval information.
[3] Byrd, J. C., et al. (2021). Pirtobrutinib in relapsed or refractory mantle-cell lymphoma. New England Journal of Medicine, 387(18), 1663-1674.
[4] National Cancer Institute. Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version.